Polycythaemia vera

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
HDAC inhibitor 1 substance
Unknown / small molecule 1 substance
Phase III: 2 Phase IV: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

2 trials
  • Italfarmaco S.p.A. Commercial
    GIVINOSTAT
    2022-502276-23-00 11 countries 2024 n=219 Orphan
    Recruiting
  • Protagonist Therapeutics Inc. Commercial
    RUSFERTIDE
    2023-509750-58-00 11 countries 2022 n=102 Orphan
    Ended

Phase IV

1 trial
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502338-20-00 1 country 2023 n=300
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Italfarmaco S.p.A. Commercial 1 Phase III 1
Protagonist Therapeutics Inc. Commercial 1 Phase III 0
Novartis Pharma AG Commercial 1 Phase IV 0
New trials by year
2022
1
2023
1
2024
1
← All indication landscapes